Alpha-conotoxin AuIB isomers exhibit distinct inhibitory mechanisms and differential sensitivity to stoichiometry of alpha3beta4 nicotinic acetylcholine receptors.
Non-native disulfide isomers of alpha-conotoxins are generally inactive although some unexpectedly demonstrate comparable or enhanced bioactivity. The actions of "globular" and "ribbon" isomers of alpha-conotoxin AuIB have been characterized on alpha3beta4 nicotinic acetylcholine receptors (nAChRs) heterologously expressed in Xenopus oocytes. Using two-electrode voltage clamp recording, we showed that the inhibitory efficacy of the ribbon isomer of AuIB is limited to approximately 50%. The maximal inhibition was stoichiometry-dependent because altering alpha3:beta4 RNA injection ratios either increased AuIB(ribbon) efficacy (10alpha:1beta) or completely abolished blockade (1alpha:10beta). In contrast, inhibition by AuIB(globular) was independent of injection ratios. ACh-evoked current amplitude was largest for 1:10 injected oocytes and smallest for the 10:1 ratio. ACh concentration-response curves revealed high (HS, 1:10) and low (LS, 10:1) sensitivity alpha3beta4 nAChRs with corresponding EC(50) values of 22.6 and 176.9 microM, respectively. Increasing the agonist concentration antagonized the inhibition of LS alpha3beta4 nAChRs by AuIB(ribbon), whereas inhibition of HS and LS alpha3beta4 nAChRs by AuIB(globular) was unaffected. Inhibition of LS and HS alpha3beta4 nAChRs by AuIB(globular) was insurmountable and independent of membrane potential. Molecular docking simulation suggested that AuIB(globular) is likely to bind to both alpha3beta4 nAChR stoichiometries outside of the ACh-binding pocket, whereas AuIB(ribbon) binds to the classical agonist-binding site of the LS alpha3beta4 nAChR only. In conclusion, the two isomers of AuIB differ in their inhibitory mechanisms such that AuIB(ribbon) inhibits only LS alpha3beta4 nAChRs competitively, whereas AuIB(globular) inhibits alpha3beta4 nAChRs irrespective of receptor stoichiometry, primarily by a non-competitive mechanism.
Grishin
Anton A
AA
Health Innovations Research Institute, RMIT University, Melbourne, Victoria 3083, Australia.
Wang
Ching-I A
CI
Muttenthaler
Markus
M
Alewood
Paul F
PF
Lewis
Richard J
RJ
Adams
David J
DJ
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D020916:Conotoxins / Q000737:chemistry* / Q000494:pharmacology*; D004220:Disulfides / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D015640:Ion Channel Gating / Q000187:drug effects; D007536:Isomerism; D008958:Models, Molecular; D018733:Nicotinic Antagonists / Q000737:chemistry* / Q000494:pharmacology*; D009865:Oocytes / Q000187:drug effects / Q000378:metabolism; D011485:Protein Binding / Q000187:drug effects; D021122:Protein Subunits / Q000819:agonists / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism; D051381:Rats; D011978:Receptors, Nicotinic / Q000737:chemistry* / Q000378:metabolism*; D014982:Xenopus laevis
D020916:Conotoxins; D004220:Disulfides; D018733:Nicotinic Antagonists; D021122:Protein Subunits; D011978:Receptors, Nicotinic; C115558:conotoxin AuIB; C403530:nicotinic receptor alpha3beta4; D000109:Acetylcholine
J Neurochem. 2009 Nov;111(4):934-44
19712060
Neuron. 2004 Mar 25;41(6):907-14
15046723
J Neurosci. 2008 Oct 22;28(43):10943-51
18945902
Int J Biochem Cell Biol. 2006;38(8):1254-76
16520081
Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W116-8
16844972
EMBO J. 2007 Aug 22;26(16):3858-67
17660751
Mol Pharmacol. 2006 Aug;70(2):755-68
16720757
FEBS Lett. 2003 Nov 6;554(1-2):219-23
14596943
Bioinformatics. 2007 Nov 1;23(21):2947-8
17846036
Science. 1991 Jul 12;253(5016):164-70
1853201
Biochemistry. 1997 Aug 5;36(31):9581-7
9236004
J Biol Chem. 1997 Sep 5;272(36):22531-7
9278406
J Mol Biol. 2007 Jun 15;369(4):895-901
17481657
Mol Pharmacol. 2003 Feb;63(2):332-41
12527804
J Physiol. 2000 Dec 15;529 Pt 3:565-77
11118490
J Mol Biol. 2005 Mar 4;346(4):967-89
15701510
Nature. 2001 May 17;411(6835):269-76
11357122
J Biol Chem. 2006 Aug 25;281(34):24745-55
16790424
Neuropharmacology. 2009 Jan;56(1):237-46
18723036
Mol Pharmacol. 2006 Feb;69(2):558-63
16269534
J Mol Neurosci. 2006;30(1-2):95-6
17192644
J Neurosci. 2003 Oct 8;23(27):9004-15
14534234
Methods Enzymol. 2003;374:461-91
14696385
Int J Pept Protein Res. 1992 Sep-Oct;40(3-4):180-93
1478777
J Physiol. 1991;440:95-112
1725184
J Biol Chem. 2005 Aug 26;280(34):30460-8
15929983
J Neurosci. 2008 Jul 2;28(27):6884-94
18596163
Acta Pharmacol Sin. 2009 Jun;30(6):771-83
19448650
J Neurosci. 1998 Nov 1;18(21):8571-9
9786965
Mol Pharmacol. 1998 Dec;54(6):1124-31
9855643
Br J Pharmacol. 2009 Mar;156(6):970-81
19366353
Mol Pharmacol. 2008 Jun;73(6):1796-807
18337473
J Biol Chem. 2002 Dec 13;277(50):48849-57
12376538
Mol Pharmacol. 2007 Mar;71(3):769-76
17132685
Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W89-93
15980588
J Gen Physiol. 2004 Jun;123(6):697-708
15148328
Nat Neurosci. 2007 Aug;10(8):953-62
17643119
J Neurosci. 2009 Jul 8;29(27):8734-42
19587280
Proteins. 2000 May 1;39(2):178-94
10737939
Biochemistry. 2004 Dec 28;43(51):16019-26
15609996
J Biol Chem. 2003 Jan 10;278(2):757-64
12384509
EMBO J. 2005 Oct 19;24(20):3635-46
16193063
Nat Struct Mol Biol. 2005 Jul;12(7):582-8
15951818